The sensor is inserted by a trained health care provider in the upper arm and continuously measures glucose for up to 6 months.
Eversense is the only CGM system with a over 6 month subcutaneous sensor — giving patients the longest wear time ever, along with exceptional accuracy up to 6 months. Increase your patients’ satisfaction and utilization and help them break free from the burden of frequent, inconvenient and sometimes painful self-insertions.
One sensor continuously for up to 6 months
Exceptional accuracy over 6 months, including with hypoglycemia
Easy on, easy-off transmitter to fit your lifestyle**
Distinct on-body vibe alerts when high or low
Silicone-based fresh daily adhesive for comfort (can help reduce skin reactions)
Consistent accuracy over 6 months
While all CGM systems use transcutaneous sensors that are inserted into the skin and last 7-14 days, the Eversense sensor is inserted completely under the skin. The Eversense CGM system lasts up to 6 months — eliminating the hassle and discomfort of frequent sensor insertions. Simply put, it makes managing your diabetes so much easier.
Patients with diabetes receive clinical benefit from continuous glucose monitoring when the sensor is worn more than 70% of the time.1 Limitations of CGM technology have led some to discontinue use after just the first year.2
Current CGM users cited key improvements they desire.3
Multi-site prospective pivotal clinical trial of 181 type 1 and type 2 diabetes participants.
Only 2 sensors per year with
Eversense E3 vs 26-52 sensor changes with traditional CGMS
8.5% Overall MARD4*
Proven high user acceptability
Reported improved confidence over control of their diabetes5
Reported less day-to-day burden5
were more motivated to keep up
with diabetes management5
of users would choose to be inserted again5
Browse training videos, guides and more.
Understand the three components of Eversense Reimbursement.
To learn more about Eversense CGM and how to get started:
Give us a call at 1-844-736-7348
Email us at
*Eversense E3 CGM Systems include the Eversense E3 Sensor with sacrificial boronic acid (SBA) design modification. In the PROMISE study, MARD of 8.5% was observed in the E3 Sensor with SBA, and MARD of 9.1% was observed in primary sensor without SBA design modification.
†On a compatible android or iOS device. For a full list of compatible devices, please click here.
**There is no glucose data generated when the transmitter is off
***The opinions expressed belong solely to the individual. This information provides general information only. It is not intended to be used as medical advice, diagnosis or treatment and should not replace the advice of a Health Care Provider.
1. Battelino T, Danne T, Bergenstal R, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From The International Consensus on Time in Range. Diabetes Care 2019; 42: 1595-1597. doi: 10.2337/dci19-0028.
2. Yu, S., & Varughese B, et al. (2018). Healthcare resource waste associated with Patient Nonadherence and Early discontinuation of Traditional continuous glucose monitoring in Real-world Settings: A MULTICOUNTRY ANALYSIS. Diabetes Technology & Therapeutics, 20(6), 420-427. doi: 10.1089/dia.2017.0435.
3. dQ&A Q1 2021 Panel survey.
4. Garg S. et al.. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9. DOI: 10.1089/dia.2021.0182.
5. Barnard et al. Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology 2018, Vol. 12(3) 634–638